Advertisement
News
Advertisement

BioRelix lands $2.4M financing

Thu, 12/23/2010 - 6:33am
Mass High Tech: The Journal of New England Technology

BioRelix Inc., a biotech based in New Haven, Conn., has taken in $2.4 million of a planned $4.8 million debt and warrants financing, according to a filing with the U.S. Securities and Exchange Commission.

The company develops infectious disease treatments using RNA targets called RiboSwitches, which are found in bacteria and fungi, the BioRelix website explains. It was founded upon scientific research by Ronald Breaker, who discovered RiboSwitches in his lab at Yale University.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading